Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis
Authors
Keywords
-
Journal
Annals of the New York Academy of Sciences
Volume 1329, Issue 1, Pages 33-44
Publisher
Wiley
Online
2014-08-26
DOI
10.1111/nyas.12512
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Changes in cognition, arm function and lower body function after Slow-Release Fampridine treatment
- (2014) HB Jensen et al. Multiple Sclerosis Journal
- Recommendations for the Use of Prolonged-Release Fampridine in Patients with Multiple Sclerosis (MS)
- (2013) Jana Lizrova Preiningerova et al. CNS Neuroscience & Therapeutics
- Gait characteristics of multiple sclerosis patients in the absence of clinical disability
- (2013) Leandro Alberto Calazans Nogueira et al. DISABILITY AND REHABILITATION
- Pharmacokinetics of dalfampridine extended release 7.5-mg tablets in healthy subjects and individuals with mild and moderate renal impairment: An open-label study
- (2013) Emil Samara et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Long-term effects of dalfampridine in patients with multiple sclerosis
- (2013) T. Ruck et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study
- (2013) Michelle H Cameron et al. Multiple Sclerosis Journal
- Disability in multiple sclerosis: A reference for patients and clinicians
- (2013) I. Kister et al. NEUROLOGY
- Two phase 3, multicenter, randomized, placebo-controlled clinical trials of fampridine-SR for treatment of spasticity in chronic spinal cord injury
- (2013) D D Cardenas et al. SPINAL CORD
- Sustained-Release Fampridine (4-Aminopyridine) in Multiple Sclerosis: Efficacy and Impact on Motor Function
- (2013) Meheroz H. Rabadi et al. Drugs in research & development
- Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US
- (2013) Michele Jara et al. Neuropsychiatric Disease and Treatment
- Muscular and Gait Abnormalities in Persons With Early Onset Multiple Sclerosis
- (2013) Alon Kalron et al. Journal of Neurologic Physical Therapy
- Social and economic burden of walking and mobility problems in multiple sclerosis
- (2012) James Pike et al. BMC Neurology
- Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosis
- (2012) Scott Weir et al. CURRENT MEDICAL RESEARCH AND OPINION
- Clinical overview of the seizure risk of dalfampridine
- (2012) Sheryl R. Haut et al. Expert Opinion On Drug Safety
- Quantifying gait abnormalities in persons with multiple sclerosis with minimal disability
- (2012) Jacob J. Sosnoff et al. GAIT & POSTURE
- Body-worn motion sensors detect balance and gait deficits in people with multiple sclerosis who have normal walking speed
- (2012) R.I. Spain et al. GAIT & POSTURE
- The impact of slower walking speed on activities of daily living in patients with multiple sclerosis
- (2012) M. Yildiz INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Final Data from Open-Label Extension Studies of Dalfampridine Extended Release Tablets in Multiple Sclerosis (P04.128)
- (2012) A. Goodman et al. NEUROLOGY
- Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis
- (2011) Jeffrey Dunn et al. CURRENT MEDICAL RESEARCH AND OPINION
- Symptomatic Management in Multiple Sclerosis
- (2011) Lawrence M. Samkoff et al. NEUROLOGIC CLINICS
- Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice
- (2011) João Carlos Correia de Sa et al. Therapeutic Advances in Neurological Disorders
- A phase 3 trial of extended release oral dalfampridine in multiple sclerosis
- (2010) Andrew D. Goodman et al. ANNALS OF NEUROLOGY
- Economic Burden of Multiple Sclerosis
- (2010) Huseyin Naci et al. PHARMACOECONOMICS
- Impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis
- (2010) Jeffrey Dunn Expert Review of Pharmacoeconomics & Outcomes Research
- Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-Release 10-mg tablets in patients with multiple sclerosis: A 2-week, open-label, follow-up study
- (2009) Timothy Vollmer et al. CLINICAL THERAPEUTICS
- Impact of loss of mobility on instrumental activities of daily living and socioeconomic status in patients with MS
- (2009) A.R. Salter et al. CURRENT MEDICAL RESEARCH AND OPINION
- Contribution of impaired mobility to patient burden in multiple sclerosis
- (2009) Matthew H. Sutliff CURRENT MEDICAL RESEARCH AND OPINION
- Assessment of the cardiac safety of fampridine-SR sustained-release tablets in a thorough QT/QTc evaluation at therapeutic and supratherapeutic doses in healthy individuals
- (2009) Barrie March et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Single-Dose Pharmacokinetics of Sustained-Release Fampridine (Fampridine-SR) in Healthy Volunteers and Adults With Renal Impairment
- (2009) William Smith et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Severe Accidental Overdose of 4-Aminopyridine Due to a Compounding Pharmacy Error
- (2009) Eric Schwam JOURNAL OF EMERGENCY MEDICINE
- Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial
- (2009) Andrew D Goodman et al. LANCET
- Efficacy and Safety of a Hip Flexion Assist Orthosis in Ambulatory Multiple Sclerosis Patients
- (2008) Matthew H. Sutliff et al. ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
- Gait analysis in multiple sclerosis: Characterization of temporal–spatial parameters using GAITRite functional ambulation system
- (2008) Uri Givon et al. GAIT & POSTURE
- Multiple sclerosis
- (2008) Alastair Compston et al. LANCET
- 4-AMINOPYRIDINE TOXICITY WITH UNINTENTIONAL OVERDOSE IN FOUR PATIENTS WITH MULTIPLE SCLEROSIS
- (2008) J. M. Burton et al. NEUROLOGY
- Dose comparison trial of sustained-release fampridine in multiple sclerosis
- (2008) A. D. Goodman et al. NEUROLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started